CN105087457B - A kind of method that RBS optimizations improve α ketoisocaproate yield - Google Patents
A kind of method that RBS optimizations improve α ketoisocaproate yield Download PDFInfo
- Publication number
- CN105087457B CN105087457B CN201510575189.1A CN201510575189A CN105087457B CN 105087457 B CN105087457 B CN 105087457B CN 201510575189 A CN201510575189 A CN 201510575189A CN 105087457 B CN105087457 B CN 105087457B
- Authority
- CN
- China
- Prior art keywords
- pet28a
- rbs
- recombination bacillus
- coli
- bacillus coli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 23
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 title abstract description 6
- 238000005457 optimization Methods 0.000 title abstract description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 18
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- 239000000758 substrate Substances 0.000 claims abstract description 10
- 241000894006 Bacteria Species 0.000 claims abstract description 7
- QUKRTJQSGPLQKQ-UHFFFAOYSA-N 5-methylsulfonyl-3h-1,3-benzoxazol-2-one Chemical compound CS(=O)(=O)C1=CC=C2OC(=O)NC2=C1 QUKRTJQSGPLQKQ-UHFFFAOYSA-N 0.000 claims description 23
- 241000588724 Escherichia coli Species 0.000 claims description 17
- 150000008575 L-amino acids Chemical class 0.000 claims description 9
- 238000000855 fermentation Methods 0.000 claims description 8
- 230000004151 fermentation Effects 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 7
- 239000001888 Peptone Substances 0.000 claims description 5
- 108010080698 Peptones Proteins 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 235000019319 peptone Nutrition 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000002054 inoculum Substances 0.000 claims description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 241000588767 Proteus vulgaris Species 0.000 claims description 3
- 229940041514 candida albicans extract Drugs 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 229940007042 proteus vulgaris Drugs 0.000 claims description 3
- 238000003259 recombinant expression Methods 0.000 claims description 3
- 239000012138 yeast extract Substances 0.000 claims description 3
- 244000110797 Polygonum persicaria Species 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 238000005215 recombination Methods 0.000 claims 6
- 230000006798 recombination Effects 0.000 claims 6
- 241000196324 Embryophyta Species 0.000 claims 1
- 241000305071 Enterobacterales Species 0.000 claims 1
- 239000007836 KH2PO4 Substances 0.000 claims 1
- 230000009615 deamination Effects 0.000 claims 1
- 238000006481 deamination reaction Methods 0.000 claims 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract description 6
- 230000003197 catalytic effect Effects 0.000 abstract description 6
- 238000010353 genetic engineering Methods 0.000 abstract description 3
- 230000009466 transformation Effects 0.000 abstract description 2
- 235000005772 leucine Nutrition 0.000 abstract 2
- 239000012530 fluid Substances 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 150000002614 leucines Chemical class 0.000 abstract 1
- 229960003136 leucine Drugs 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 235000019454 L-leucine Nutrition 0.000 description 6
- 239000004395 L-leucine Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011218 seed culture Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-N isocaproic acid Chemical compound CC(C)CCC(O)=O FGKJLKRYENPLQH-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical group [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 235000019838 diammonium phosphate Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- HWCVOHTUMBPBSE-UHFFFAOYSA-N n',n'-diethyloxamide Chemical compound CCN(CC)C(=O)C(N)=O HWCVOHTUMBPBSE-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
技术领域technical field
本发明涉及一种RBS优化提高α-酮异己酸产量的方法,属于基因工程领域。The invention relates to a method for optimizing the production of α-ketoisocaproic acid by optimizing RBS, and belongs to the field of genetic engineering.
背景技术Background technique
α-酮异己酸(KIC),又称α-氧代异戊酸,是亮氨酸合成与分解的中间代谢产物,它作为亮氨酸的无氮替代物,能够作为肾病患者的营养补充剂。除此之外,KIC可以在饲料、保健品、化学合成领域。α-Ketoisocaproic acid (KIC), also known as α-oxoisovaleric acid, is an intermediate metabolite in the synthesis and decomposition of leucine. As a nitrogen-free substitute for leucine, it can be used as a nutritional supplement for patients with kidney disease . In addition, KIC can be used in the fields of feed, health products, and chemical synthesis.
目前KIC的生产方法主要是化学合成法,主要包括二乙基草酰胺与格氏试剂加成产物的水解反应、双羰基化法、海因法等等。这些方法反应条件苛刻,都需要特殊结构作为起始物,或者价格昂贵的催化剂(如八羟基二钴与零价钯的络合物),并且都需要经过多步反应作为起始物,较难用于生产实践和工业化大规模生产。微生物转化或者酶转化法,可以替代传统的化学合成法来生产α-酮异己酸。目前,可以通过大肠杆菌表达来自Proteusvulgaris的L-氨基酸脱氨酶,实现底物亮氨酸向酮异己酸的高转化高产率的转化过程。At present, the production methods of KIC are mainly chemical synthesis methods, mainly including the hydrolysis reaction of the addition product of diethyl oxamide and Grignard reagent, double carbonylation method, Heine method and so on. These methods reaction conditions are harsh, all need special structure as starting material, or expensive catalyst (as the complex compound of octahydroxy dicobalt and zero-valent palladium), and all need through multi-step reaction as starting material, more difficult For production practice and industrialized mass production. Microbial conversion or enzymatic conversion can replace traditional chemical synthesis to produce α-ketoisocaproic acid. At present, the L-amino acid deaminase from Proteusvulgaris can be expressed in Escherichia coli to realize a high-yield conversion process of substrate leucine to ketoisocaproic acid.
然而,目前的α-酮异己酸在转化过程中的产量和转化率还较低,不够达到工业化生产的要求,所以需要进一步提高α-酮异己酸的产量。本发明旨在通过对核糖体结合位点进行优化,提高L-氨基酸脱氨酶的翻译表达水平,以期进一步提高α-酮异己酸的产量。However, the yield and conversion rate of the current α-ketoisocaproic acid in the conversion process are still low, which is not enough to meet the requirements of industrial production, so it is necessary to further increase the yield of α-ketoisocaproic acid. The invention aims at improving the translation expression level of L-amino acid deaminase by optimizing the ribosome binding site, so as to further increase the output of α-ketoisocaproic acid.
发明内容Contents of the invention
本发明要解决的第一个技术问题是提供一种L-氨基酸脱氨酶活力提高的重组大肠杆菌,是将来自普通变形杆菌(P.vulgaris)的编码L-氨基酸脱氨酶的基因,以pET28a(+)为表达载体进行重组表达,所述载体pET28a(+)的原始RBS序列区域有一个或者多个碱基发生突变。The first technical problem to be solved by the present invention is to provide a recombinant escherichia coli with improved activity of L-amino acid deaminase, which is the gene encoding L-amino acid deaminase from P. pET28a(+) is an expression vector for recombinant expression, and one or more bases are mutated in the original RBS sequence region of the vector pET28a(+).
所述载体pET28a(+)的原始RBS序列是302bp-307bp的AAGGAG序列。The original RBS sequence of the vector pET28a(+) is an AAGGAG sequence of 302bp-307bp.
在本发明的一种实施方式中,所述突变是载体pET28a(+)的原始RBS序列突变为CTGCGG、CTACGG、CGGTTA或TATGGT。In one embodiment of the present invention, the mutation is that the original RBS sequence of the vector pET28a(+) is mutated into CTGCGG, CTACGG, CGGTTA or TATGGT.
本发明要解决的第二个技术问题是提供一种构建所述重组大肠杆菌的方法,是将来自普通变形杆菌(P.vulgaris)的编码L-氨基酸脱氨酶的基因,与pET28a(+)连接,得到重组表达载体pET28a-lad,以pET28a-lad为模板,通过PCR扩增的方法,将RBS编码序列突变后,再转入大肠杆菌,筛选得到重组菌。The second technical problem to be solved by the present invention is to provide a method for constructing the recombinant escherichia coli, which is to combine the gene encoding L-amino acid deaminase from Proteus vulgaris (P.vulgaris) with pET28a(+) The recombinant expression vector pET28a-lad was obtained by connection, and the pET28a-lad was used as a template to mutate the RBS coding sequence by PCR amplification, and then transformed into Escherichia coli, and the recombinant bacteria were screened.
在本发明的一种实施方式中,所述大肠杆菌是E.coli BL21(DE3)。In one embodiment of the present invention, the Escherichia coli is E. coli BL21(DE3).
本发明还提供了一种提高α-酮异己酸产量的方法,是利用所述L-氨基酸脱氨酶活力提高的重组大肠杆菌作为全细胞催化剂,转化底物L-亮氨酸得到α-酮异己酸。The present invention also provides a method for increasing the production of α-ketoisocaproic acid, which is to use the recombinant Escherichia coli with improved L-amino acid deaminase activity as a whole-cell catalyst to convert the substrate L-leucine to obtain α-ketone isocaproic acid.
在本发明的一种实施方式中,以含0.8g/L重组大肠杆菌全细胞、100mM/L底物L-亮氨酸的体系,在37℃下转化生成α-酮异己酸,并每隔2h流加100mM L-亮氨酸,共流加6次,共转化反应24h。In one embodiment of the present invention, α-ketoisocaproic acid is transformed into α-ketoisocaproic acid at 37°C with a system containing 0.8g/L recombinant E. coli whole cells and 100mM/L substrate L-leucine, and every 100mM L-leucine was added for 2h, and the flow was added 6 times for a total of 24h.
在本发明的一种实施方式中,所述重组大肠杆菌全细胞的获得,是将种子培养液按2%的接种量接种到发酵培养基中,37℃培养至OD600为0.6,添加终浓度0.4mM的IPTG,37℃诱导5h,收集细胞。In one embodiment of the present invention, the whole cells of recombinant Escherichia coli are obtained by inoculating the seed culture solution into the fermentation medium at an inoculum size of 2%, culturing at 37°C until the OD600 is 0.6, and adding the final concentration of 0.4mM IPTG, induced for 5h at 37°C, and the cells were collected.
所述的种子培养与发酵培养基:种子培养基(/L):蛋白胨1g,酵母粉0.5g,NaCl1g,蒸馏水定容至100mL。发酵培养基(/L):蛋白胨12g,酵母提取物24g,甘油4mL,各组分溶解后高压灭菌。冷却到60℃,再加100mL灭菌的17mmol/L KH2PO4和72mmol/LK2HPO4的溶液(2.31g的KH2PO4和12.54g的K2HPO4溶于水中,终体积为100mL,高压灭菌)。The seed culture and fermentation medium: seed medium (/L): peptone 1g, yeast powder 0.5g, NaCl 1g, distilled water to 100mL. Fermentation medium (/L): 12g of peptone, 24g of yeast extract, 4mL of glycerin, each component was dissolved and then autoclaved. Cool to 60°C, add 100mL sterilized solution of 17mmol/L KH 2 PO 4 and 72mmol/L K 2 HPO 4 (dissolve 2.31g of KH 2 PO 4 and 12.54g of K 2 HPO 4 in water, the final volume is 100 mL, autoclaved).
本发明对表达载体pET28a-lad的RBS序列进行改造,提高酶的翻译效率、提高酶活,并构建了可以高效生产的菌种从而提高α-酮异己酸产量。与现有技术相比,本发明的α-酮异己酸产量可以达到81.41g/L,底物转化率88.66%。本转化方法反应条件温和,对环境污染少,而且底物选择性高,目的产物专一,反应速率快,产物得率高,而且生产周期短,只需24h。此方法有利于解决化学合成法中的污染严重,步骤繁琐等问题,而且工艺简单,易于控制,方便推广应用。The invention transforms the RBS sequence of the expression vector pET28a-lad, improves the translation efficiency of the enzyme, improves the enzyme activity, and constructs a strain capable of high-efficiency production so as to increase the output of α-ketoisocaproic acid. Compared with the prior art, the yield of α-ketoisocaproic acid of the present invention can reach 81.41g/L, and the substrate conversion rate is 88.66%. The conversion method has mild reaction conditions, less environmental pollution, high substrate selectivity, specific target product, fast reaction rate, high product yield, and short production cycle, only 24 hours. The method is beneficial to solve the problems of serious pollution and cumbersome steps in the chemical synthesis method, and the process is simple, easy to control, and convenient to popularize and apply.
附图说明Description of drawings
图1 RBS优化的催化活力变化。Fig. 1 Changes in catalytic activity of RBS optimization.
图2 RBS优化后的α-酮异己酸产量。Fig. 2 Production of α-ketoisocaproic acid after RBS optimization.
具体实施方式Detailed ways
材料与方法Materials and Methods
LB培养基:蛋白胨1g,酵母粉0.5g,NaCl 1g,自来水定容至100mL。LB medium: peptone 1g, yeast powder 0.5g, NaCl 1g, tap water to 100mL.
发酵培养基(TB培养基):蛋白胨12g,酵母提取物24g,甘油4mL。各组分溶解后高压灭菌。冷却到60℃,再加100mL灭菌的含有17mmol/L KH2PO4和72mmol/L K2HPO4的溶液。Fermentation medium (TB medium): peptone 12g, yeast extract 24g, glycerol 4mL. The components are dissolved and autoclaved. Cool to 60°C, and add 100 mL of a sterilized solution containing 17 mmol/L KH 2 PO 4 and 72 mmol/L K 2 HPO 4 .
样品制备:取1mL转化后的溶液,在10,000rpm下离心10min,取上清液稀释后,经过0.45μm滤膜过滤,滤液供液相色谱分析。Sample preparation: Take 1 mL of the converted solution, centrifuge at 10,000 rpm for 10 min, take the supernatant and dilute it, filter it through a 0.45 μm filter membrane, and use the filtrate for liquid chromatography analysis.
α-酮异己酸的含量测定:Agilent 1100高效液相色谱仪(配紫外可见检测器)采用ZORBAX SB-Aq(4.6×250mm,5μm)色谱柱,流动相为0.01mol/L的磷酸氢二铵溶液(pH2.50)-甲醇溶液(90:10,v/v),流速为0.8mL/min,柱温为35℃,在紫外检测波长为203nm下检测。Determination of the content of α-ketoisocaproic acid: Agilent 1100 high performance liquid chromatography (equipped with UV-visible detector) adopts ZORBAX SB-Aq (4.6×250mm, 5μm) chromatographic column, and the mobile phase is diammonium hydrogen phosphate of 0.01mol/L Solution (pH2.50)-methanol solution (90:10, v/v), the flow rate is 0.8mL/min, the column temperature is 35°C, and the ultraviolet detection wavelength is 203nm.
实施例1RBS突变体文库的构建The construction of embodiment 1RBS mutant library
以pET28a-lad(构建方法参见申请号为201410050399.4,公布号为CN 103789247A的专利申请)为模板,以正向引物为5’-NNNNNNATATACCATGGCGATATCTAGAAGAA-3’,反向引物为5’-CTTAAAGTTAAACAAAATTATTTCTAGAGG-3’为引物进行PCR反应,反应产物经过Dpn I消化其模板后,使用DNA柱式回收试剂盒回收,加入磷酸化酶进行末端磷酸化,加入Solution I连接酶16℃连接过夜。将连接后的质粒转入E.coli BL21(DE3)的感受态中,涂布在卡纳青霉素抗性的平板上。Using pET28a-lad (see application number 201410050399.4 for the construction method, patent application publication number CN 103789247A) as a template, the forward primer is 5'- NNNNNN ATATACCATGGCGATATCTAGAAGAA-3', and the reverse primer is 5'-CTTAAAGTTAAACAAAAATTATTTCTAGAGG-3' PCR reaction was performed for primers. After the reaction product was digested with Dpn I, the template was recovered using a DNA column recovery kit, phosphorylase was added for terminal phosphorylation, and Solution I ligase was added to ligate overnight at 16°C. The ligated plasmid was transformed into the competent E.coli BL21(DE3), and spread on a kanapenicillin-resistant plate.
实施例2L-氨基酸脱氨酶催化活力提高的突变体筛选Example 2 L-amino acid deaminase catalytic activity improved mutant screening
将实施例1中的单菌落用灭过菌的牙签挑到含有700μL LB培养基的96孔深孔板中,37℃震荡过夜培养,以2%的接种量接种到含有700μL发酵培养基的96孔深孔板中,37℃震荡培养到OD600为0.6,加入0.4mM IPTG诱导后3h收集菌体,3400rpm离心10min后,在深孔板中加入1mL的100mM亮氨酸水溶液,反应10分钟后,加入100μL的1%的FeCl3溶液进行显色。Pick the single colony in Example 1 into a 96-well deep-well plate containing 700 μL LB medium with a sterilized toothpick, culture it overnight with shaking at 37° C., and inoculate it into a 96-well plate containing 700 μL fermentation medium with an inoculum size of 2%. In a deep-well plate, shake culture at 37°C until the OD 600 is 0.6, add 0.4mM IPTG and collect the bacteria 3 hours after induction, centrifuge at 3400rpm for 10min, add 1mL of 100mM leucine aqueous solution to the deep-well plate, and react for 10 minutes , add 100 μL of 1% FeCl 3 solution for color development.
实施例3全细胞转化L-亮氨酸的催化活力测定和突变体序列变化Example 3 Determination of Catalytic Activity and Sequence Changes of Mutants Converted to L-leucine by Whole Cells
将实施例2中显色为深黑色的重组大肠杆菌E.coli BL21(DE3)从LB培养基中-转接到装有25mL种子培养基的250mL的三角瓶中,过夜培养,以2%的接种量接种到50mL发酵培养基中,37℃,200r/min培养到OD600为0.6,加入0.4mM IPTG诱导,37℃培养5h后离心收集菌体进行全细胞转化。取0.8g/L细胞、100mM底物L-亮氨酸,37℃反应0.5h,12000rpm离心2min,取上清测定α-酮异己酸含量。The recombinant escherichia coli E.coli BL21 (DE3) that develops the color in embodiment 2 is dark black from LB culture medium-transfer in the Erlenmeyer flask of 250mL that 25mL seed culture medium is housed, cultivate overnight, with 2% The inoculum was inoculated into 50 mL of fermentation medium, cultured at 37°C, 200r/min until the OD 600 was 0.6, induced by adding 0.4mM IPTG, cultured at 37°C for 5h, and collected by centrifugation for whole cell transformation. Take 0.8g/L cells, 100mM substrate L-leucine, react at 37°C for 0.5h, centrifuge at 12000rpm for 2min, and take the supernatant to measure the content of α-ketoisocaproic acid.
根据公式计算获得酶活力。(其中C(KIC)是测定的α-酮异己酸含量,DCW为菌体干重0.8g/L,T为反应时间0.5h)。其突变体催化活力如图1所示。其中RBS3、RBS4、RBS6、RBS8的催化活力相对原始菌活力提高20%左右。According to the formula Enzyme activity was calculated. (Wherein C (KIC) is the determined α-ketoisocaproic acid content, DCW is 0.8g/L of bacterium dry weight, T is the reaction time 0.5h). The catalytic activity of its mutants is shown in Figure 1. Among them, the catalytic activities of RBS3, RBS4, RBS6 and RBS8 were about 20% higher than that of the original bacteria.
经过序列比对,突变体RBS3、RBS4、RBS6、RBS8的RBS序列分别突变为CTGCGG,CTACGG,CGGTTA,TATGGT。After sequence alignment, the RBS sequences of mutants RBS3, RBS4, RBS6, and RBS8 were mutated into CTGCGG, CTACGG, CGGTTA, and TATGGT, respectively.
实施例4全细胞转化合成α-酮异己酸的方法Example 4 Whole Cell Transformation Method for Synthesizing α-Ketoisocaproic Acid
根据如上培养方法培养后,收集RBS3、RBS4、RBS6、RBS8的菌体,在0.8g/L菌体、100mM/L底物L-亮氨酸,每2h流加100mM亮氨酸(流加到12h,共计6次),37℃条件下,转化24h。稀释后,12000rpm离心2min离心,取上清测定含量。其产量测定结果如图2所示。其中RBS4、RBS6、RBS8的产量高于原始菌株,最大产量达到81.41g/L,转化率达到88.66%。After cultivating according to the above culture method, collect the thalli of RBS3, RBS4, RBS6, and RBS8, add 100 mM leucine every 2 h at 0.8 g/L thalline, 100 mM/L substrate L-leucine (flow added to 12h, 6 times in total), at 37°C, transform for 24h. After dilution, centrifuge at 12000rpm for 2min, and take the supernatant to measure the content. The yield measurement results are shown in Figure 2. Among them, the output of RBS4, RBS6 and RBS8 was higher than that of the original strain, the maximum output reached 81.41g/L, and the transformation rate reached 88.66%.
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。Although the present invention has been disclosed above with preferred embodiments, it is not intended to limit the present invention. Any person familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore The scope of protection of the present invention should be defined by the claims.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510575189.1A CN105087457B (en) | 2015-09-10 | 2015-09-10 | A kind of method that RBS optimizations improve α ketoisocaproate yield |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510575189.1A CN105087457B (en) | 2015-09-10 | 2015-09-10 | A kind of method that RBS optimizations improve α ketoisocaproate yield |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105087457A CN105087457A (en) | 2015-11-25 |
CN105087457B true CN105087457B (en) | 2018-04-10 |
Family
ID=54568793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510575189.1A Active CN105087457B (en) | 2015-09-10 | 2015-09-10 | A kind of method that RBS optimizations improve α ketoisocaproate yield |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105087457B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106399216B (en) * | 2016-11-16 | 2019-12-10 | 江南大学 | single-cell factory for efficiently synthesizing alpha-aminobutyric acid and construction and application thereof |
CN108103120B (en) * | 2017-12-19 | 2020-08-04 | 江南大学 | A method for the synthesis of L-aspartic acid from maleic acid by double-enzyme-coupled whole-cell catalysis |
CN108587993B (en) * | 2018-04-25 | 2020-08-04 | 江南大学 | Method for high-yield α -ketoisocaproic acid by enzymatic catalysis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013151174A1 (en) * | 2012-04-02 | 2013-10-10 | Ajinomoto Co.,Inc. | Auto-inducible expression system, and the use thereof for producing useful metabolites using a bacterium of the family enterobacteriaceae |
CN103789247A (en) * | 2014-02-14 | 2014-05-14 | 江南大学 | Method for producing alpha-ketoisocaproate by whole-cell transformation |
-
2015
- 2015-09-10 CN CN201510575189.1A patent/CN105087457B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013151174A1 (en) * | 2012-04-02 | 2013-10-10 | Ajinomoto Co.,Inc. | Auto-inducible expression system, and the use thereof for producing useful metabolites using a bacterium of the family enterobacteriaceae |
CN103789247A (en) * | 2014-02-14 | 2014-05-14 | 江南大学 | Method for producing alpha-ketoisocaproate by whole-cell transformation |
Non-Patent Citations (2)
Title |
---|
微生物酶高效异源表达策略的最新研究进展;杨海泉 等;《食品科学》;20130515;第34卷;第351-357页 * |
茶树β-1, 3葡聚糖酶基因在大肠杆菌中的优化表达;高轩 等;《安徽农业大学学报》;20071015;第34卷(第4期);第543-546页 * |
Also Published As
Publication number | Publication date |
---|---|
CN105087457A (en) | 2015-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107586794B (en) | Method for producing tyrosol and hydroxytyrosol by heterologous metabolic pathway | |
CN104830815B (en) | A kind of method that α phenylpyruvic acids are efficiently produced using resting cell | |
CN103789247B (en) | Method for producing alpha-ketoisocaproate by whole-cell transformation | |
CN111269900B (en) | Preparation and application of L-amino acid deaminase mutant | |
CN108060114B (en) | A kind of Escherichia coli of fermenting and producing l-Alanine and its application | |
CN103911400B (en) | A kind of method adopting resting cell to produce α-ketoglutaric acid | |
CN103642743A (en) | Method for producing alpha-phenylpyruvic acid efficiently through whole cell transformation | |
CN106566823B (en) | Cloning and application of glutamate decarboxylase gene | |
CN105087457B (en) | A kind of method that RBS optimizations improve α ketoisocaproate yield | |
CN105567622A (en) | Recombinant Escherichia coli and application of recombinant Escherichia coli in synthesizing 3-hydroxypropionic acid | |
CN108467860A (en) | A kind of method of highly producing gamma-aminobutyric acid | |
CN110527656A (en) | Efficiently synthesize engineering bacteria and its construction method and the application of 5-Methylpyrazine-2-carboxylic acid | |
CN104131041A (en) | Production method for alpha-ketoglutaric acid | |
CN107227286B (en) | A genetically engineered bacterium with high production of succinic acid and its construction method and application | |
CN109321541B (en) | A mutant of L-amino acid oxidase | |
CN104862264B (en) | A kind of recombinant bacterium for converting production α-phenylpyruvic acid efficiency and improving | |
CN114426977A (en) | Recombinant engineering bacterium and construction method and application thereof | |
CN105647846A (en) | Recombinant bacterium providing improved efficiency in convertive production of Alpha-phenylpyruvic acid | |
KR20110012170A (en) | Rhodobacter spheroid hydrogenase or nitrogenase transformed host cell and hydrogen production method using the same | |
CN103865959A (en) | Biological synthesis method of xylosic acid | |
CN103937842B (en) | Method for increasing yield of alpha-oxoglutarate produced through whole-cell transformation | |
CN103484417B (en) | Gluconobacter oxydans improving 2-KLG fermentation yield and application thereof | |
CN113061563B (en) | Method for synthesizing L-malic acid by utilizing recombinant escherichia coli whole cell catalysis | |
CN107513525B (en) | A kind of D- mandelate dehydrogenase, gene, genetic engineering bacterium and its application | |
CN101173292B (en) | 1,3-propylene glycol redex enzyme isoenzyme variant gene Gln202ala and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |